A. Menarini Industrie Farmaceutiche Riunite has filed a patent for methods of treating cancer by administering peptides derived from EphA2 and IL-13Ra2 proteins to a subject and monitoring cancer stem cells. The patent also includes methods for monitoring treatment efficacy. GlobalData’s report on A. Menarini Industrie Farmaceutiche Riunite gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on A. Menarini Industrie Farmaceutiche Riunite, Cancer treatment biomarkers was a key innovation area identified from patents. A. Menarini Industrie Farmaceutiche Riunite's grant share as of January 2024 was 52%. Grant share is based on the ratio of number of grants to total number of patents.
Cancer treatment using epha2 or il-13ra2 peptide
A recently filed patent (Publication Number: US20230374152A1) outlines a method for treating or managing brain cancer in a subject by administering an IL-13Ra2 peptide and bevacizumab. The method involves measuring the amount of IL-13Ra2-expressing cancer stem cells in the subject, with the administration of the peptide and bevacizumab aimed at reducing these cells. The patent further details various techniques for determining the amount of IL-13Ra2-expressing cancer stem cells, including immunoassays, flow cytometry, imaging, and in vitro assays using different biological samples.
Moreover, the patent describes additional elements of the method, such as measuring the cancer stem cells before administering the treatment, comparing the results to reference samples, and incorporating helper T cell epitopes, adjuvants, and immune response modifiers. The method also includes loading the IL-13Ra2 peptide on dendritic cells and administering the treatment subcutaneously or intra-nodally. The patent specifies that the brain cancer targeted by this method can be glioma or glioblastoma. Additionally, a separate claim in the patent focuses on monitoring the efficacy of the therapy by measuring the IL-13Ra2-expressing cancer stem cells before and after treatment, with efficacy determined by a decrease in these cells post-treatment. The patent emphasizes the importance of targeting IL-13Ra2 and bevacizumab in treating brain cancer and provides a comprehensive approach for assessing and enhancing the effectiveness of the therapy.
To know more about GlobalData’s detailed insights on A. Menarini Industrie Farmaceutiche Riunite, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
